J&J Questions $158M Settlement Of Texas' Risperdal Suit

Law360, New York (March 26, 2012, 7:01 PM EDT) -- A Johnson & Johnson unit will return to court Tuesday to voice concerns about a $158 million settlement with the state of Texas over allegations that it illegally marketed antipsychotic drug Risperdal, the Texas attorney general's office confirmed Monday.

The Johnson & Johnson unit, Janssen Pharmaceuticals Inc., declined to comment on what would be discussed in court, saying the details are private and not for public disclosure.

"We are not disputing the settlement agreement that was reached in Texas. Janssen remains committed to paying the agreed...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.